Telix Pharmaceuticals Ltd
ASX:TLX

Watchlist Manager
Telix Pharmaceuticals Ltd Logo
Telix Pharmaceuticals Ltd
ASX:TLX
Watchlist
Price: 22.58 AUD 1.71% Market Closed
Market Cap: 7.6B AUD
Have any thoughts about
Telix Pharmaceuticals Ltd?
Write Note

P/E
Price to Earnings

153.4
Current
-18.4
Median
22.7
Industry
Higher than median
Higher than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
153.4
=
Market Cap
7.5B AUD
/
Net Income
49.2m AUD
All Countries
Close
Earnings Growth
AU
Telix Pharmaceuticals Ltd
ASX:TLX
Average P/E: 199.1
153.4
3 638%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 004.1 N/A
US
Abbvie Inc
NYSE:ABBV
61.5
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -242.3
42%
US
Gilead Sciences Inc
NASDAQ:GILD
891.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -131 N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
124.7
2-Years Forward
P/E
91
3-Years Forward
P/E
38.7

See Also

Discover More